Efungumab, a monoclonal antibody exhibiting antifungal properties, specifically targets HSP 90 to inhibit a conformational alteration crucial for fungal survival. It is employed in investigations concerning invasive candidiasis (IC) [1].

Efungumab（2 mg/kg，i.p.，每日一次，连续三天）在CD1小鼠念珠菌c. albicans传播性模型中有效减少了器官上的平均菌落数目，并提高了肝脏活检的阳性结果率[2]。